Results 271 to 280 of about 129,468 (342)

The association between Glycated Hemoglobin to High Density Lipoprotein Cholesterol Ratio and risk of cardiovascular diseases caused death among adult cancer survivors: evidence from NHANES 1999-2018. [PDF]

Lipids Health Dis
Sun F, Yu XJ, Huang XH, Lin J, Zhang J, Xu YM, Yang WM, Wang XZ.   +7 more
europepmc   +1 more source

Long‐term health economic evaluation of automated insulin delivery system compared with continuous subcutaneous insulin infusion pumps and CGM in a real‐world setting in Finnish paediatric and adult individuals with type 1 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The use of automated insulin delivery (AID) systems is associated with improved glycaemic control in individuals with type 1 diabetes (T1DM). However, AID systems are more expensive than other treatment modalities for T1DM. The aim of this study was to evaluate the long‐term cost‐effectiveness of AID compared to continuous subcutaneous ...
Heta‐Leena Vallivaara, Hanna A. Leppänen, Jyrki Mustonen, Antti Saari, Janne Martikainen, Reeta M. Rintamäki   +5 more
wiley   +1 more source

Association between glycated hemoglobin and the risk of neonatal respiratory distress syndrome in preterm premature rupture of membranes pregnancies. [PDF]

Sci Rep
Chen H, Tan Q, Lai S, Mai H, Wang D.
europepmc   +1 more source

The role of glycated hemoglobin (HbA1c) and serum lipid profile measurements to detect cardiovascular diseases in type 2 diabetic patients

, 2016
Muhammad Naeem, Rehman Mehmood Khattak, Mati Ur Rehman, Muhammad Nasir Khan Khattak   +3 more
openalex   +2 more sources

PIONEER REAL Spain: A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real‐world setting in Spain as part of the 13‐country PIONEER REAL programme. Materials and Methods This multicentre, prospective, non‐interventional, single‐arm study (NCT05443334) followed participants for 34–44 weeks ...
Elías Delgado Álvarez, Cristóbal Morales Portillo, Cristina Abreu Padín, Alberto Aliaga Verdugo, Ana Piera Carbonell, Aída Cadenas González, Jaime Amor Valero, Verónica González López, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Diego Bellido Guerrero   +10 more
wiley   +1 more source

Correlations Between Coronary Artery Calcium Scores and Vitamin A, the Triglyceride/High-Density Lipoprotein Ratio, and Glycated Hemoglobin in At-Risk Individuals in Saudi Arabia: A Comprehensive Cross-Sectional Study. [PDF]

J Clin Med
Al-Khlaiwi T, Alsaleh A, Alghamdi F, Abukhalaf F, Alghannam M, Alzaid S, Alslimah R, Alsadouni R, Alshammari H.   +8 more
europepmc   +1 more source

Efficacy and safety of danuglipron (PF‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This randomized, double‐blind, placebo‐controlled Phase 2b study aimed to assess the efficacy, safety, and tolerability of danuglipron (PF‐06882961), an oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in adults with obesity. Materials and Methods Eligible participants (aged 18–75 years; with obesity, without diabetes)
Clare Buckeridge, Sonia Cobain, Harold E. Bays, Osamu Matsuoka, Yasushi Fukushima, Patricia Halstead, Nikolaos Tsamandouras, Nicole Sherry, Donal N. Gorman, Aditi R. Saxena   +9 more
wiley   +1 more source

Association between glycated hemoglobin A1c levels, control status, and cognitive function in type 2 diabetes: a prospective cohort study. [PDF]

Sci Rep
Xiao Y, Hong X, Neelagar R, Mo H.
europepmc   +1 more source

Association Between Glycated Hemoglobin and the Lipid Profile at the Central Yunnan Plateau: A Retrospective Study. [PDF]

Diabetes Metab Syndr Obes
Luo B, Xu W, Ye D, Bai X, Wu M, Zhang C, Shi R.   +6 more
europepmc   +1 more source

Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Globally, cardiovascular diseases (CVDs) account for around one‐third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon‐like peptide‐1 (GLP‐1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all‐cause ...
Naveed Sattar, Luis‐Emilio García‐Pérez, Angel Rodríguez, Richa Kapoor, Adam Stefanski, Emily R. Hankosky   +5 more
wiley   +1 more source